论文部分内容阅读
目的评价沐舒坦治疗慢性阻塞性肺病患者合并肺部感染的疗效及安全性。方法观察36例慢性阻塞性肺病患者合并肺部感染治疗前后咳嗽、咯痰(排痰难易程度、痰性状、痰粘度)、肺部罗音、胸部X线、血气分析等变化。结果(1)沐舒坦治疗慢性阻塞性肺病合并肺部感染临床症状、体征的临床疗效显著;(2)观测肺部炎症时胸部X线的变化,病灶吸收效果明显;(3)治疗前后的血气分析的变化情况,显示治疗后明显改善。结论沐舒坦用于慢性阻塞性肺病合并肺部感染的临床疗效明显,尤其是痰液粘稠,排痰困难患者的疗效确切,使用安全,值得临床广泛应用。
Objective To evaluate the efficacy and safety of mucosolvan in the treatment of patients with chronic obstructive pulmonary disease complicated with pulmonary infection. Methods The changes of cough, expectoration (ease of expectoration, sputum traits, sputum viscosity), pulmonary rales, chest X ray and blood gas analysis before and after treatment of pulmonary infection in 36 patients with chronic obstructive pulmonary disease were observed. Results (1) Mucosolvan treatment of chronic obstructive pulmonary disease with clinical symptoms and signs of pulmonary infection clinical significant effect; (2) observation of lung inflammation chest X-ray changes, the lesion absorption effect is obvious; (3) before and after treatment of blood gas Analysis of the changes, showed significant improvement after treatment. Conclusion Mucosolvan is effective in the treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary infection. In particular, sputum viscosus and sputum aspirate patients have definite curative effect and safe operation, which is worth widely clinical application.